RxDoctor Payments Data

Jared Wachterman, MD

Urology · Seattle, WANPI 1740597475

Payments from drug & device makers

$1,237in general payments, 2019–2025

Across 29 payments — averaging $42.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$726
  • Urovant Sciences Inc$138
  • Olympus America Inc.$105
  • Sumitomo Pharma America, Inc.$90
  • Rochester Medical Corporation$47
  • Astellas Pharma US Inc$38
  • plus $93 from 5 others

What the payments were for

  • Travel & lodging$59648%
  • Food & beverage$62851%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,237 in reported general payments places this provider in the 40th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$60,828
Medicare patients
324
Services billed
989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron138$150,118
GemtesaVibegron56$47,172
Mirabegron ErMirabegron32$25,618
Tamsulosin Hcl725$14,559
Methenamine Hippurate122$13,161
Finasteride441$6,585
Trospium Chloride ErTrospium Chloride11$3,421
Oxybutynin Chloride ErOxybutynin Chloride69$1,836
Potassium Citrate ErPotassium Citrate23$1,740
Alfuzosin Hcl ErAlfuzosin Hcl31$847
Terazosin Hcl28$723
Trospium Chloride15$658
Solifenacin Succinate25$593
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$420
Cephalexin15$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$38$150,118138 claims
Sumitomo Pharma America, Inc.Gemtesa$90$47,17256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 274 urology providers in Washington.

Other urology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →